Clinical Trial

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

A Dutch biotech is in late-stage trials for nizubaglustat, a drug targeting rare, fatal neurological disorders. A look at the science, strategy, and hope.

A massive 15,000-patient study on an existing therapy could upend respiratory care, combat antibiotic resistance, and deliver a bottom-line windfall.

New data shows remarkable response rates for epcoritamab in a vulnerable patient group with limited options, signaling a potential paradigm shift in first-line lymphoma care.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

Atossa Therapeutics secures a crucial capital lifeline. We dissect the deal, its impact on a promising cancer drug, and what it reveals about biotech funding today.

Australian biotech Gelteq has a gel that makes bitter medicine taste good to dogs. It's more than a pet owner's dream—it's a strategic move in a $47B market.

Promising clinical trial results offer hope for cancer patients at risk of permanent, treatment-induced hearing loss, a devastating and common trade-off.

Echo IQ partners with Mayo Clinic to test its AI for cardiac risk in cancer patients, a key move for validation in the burgeoning cardio-oncology sector.

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

An Arizona nonprofit’s innovative sweepstakes, driven by a personal mission, is accelerating gene therapy for childhood blindness. A new model for impact.

A novel case study reveals how targeted chemotherapy delivery is outsmarting stubborn tumors, highlighting a metabolic victory even when size remains unchanged.

For millions, the 'why' behind infertility remains a mystery. New genomic mapping tech is finally providing answers, changing the landscape of family planning.

Major academic centers no longer hold a monopoly on medical breakthroughs. A look at how community networks are democratizing cutting-edge cancer research.

Stunning head-to-head trial data shows Takeda's zasocitinib is 2.5x more effective than its rival, signaling a major market disruption and validating a landmark deal.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.

A Swedish firm's novel cell therapy is the first of its kind in Europe, challenging the grim prognosis of pancreatic cancer and testing a new model for biotech.

Hyundai Bioscience offers a free drug for an untreatable Ebola strain. It's a bold humanitarian gesture, and a masterclass in strategic maneuvering.